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Abstract: A series of novel dimethoxyindanone embedded spiropyrrolidines were 
synthesized in ionic liquid, [bmim]Br and were evaluated for their inhibitory activities 
towards cholinesterases. Among the spiropyrrolidines, compound 4f exhibited the most 
potent activity with an IC50 value of 1.57 µM against acethylcholinesterase (AChE). 
Molecular docking simulation for the most active compound was employed with the aim of 
disclosing its binding mechanism to the active site of AChE receptor. 
Keywords: acetylcholinesterase (AChE), butyrylcholinesterase (BChE), Alzheimer’s 








Alzheimer’s disease (AD), the most common cause of dementia, is a neurodegenerative disorder 
characterized by progressive decline of memory and cognition [1]. One of the major therapeutic 
strategies adopted for primarily symptomatic AD is based on the cholinergic hypothesis targeting 
cholinesterase enzymes [2]. Inhibition of the hydrolysis of acetylcholine (ACh) by blocking its 
metabolic enzyme acetylcholinesterase (AChE) increases the ACh concentration and provides a 
possible symptomatic treatment option for AD. On the other hand, butyrylcholinesterase (BChE) has 
recently been considered as a potential target because it also plays an important role in regulating ACh 
level [3]. Although there are many ongoing research activities in the search of drugs for treating AD, 
only four drugs are currently approved for treatment and these drugs do not show potential cure rates. 
However, from academic and practical standpoints, it is still desirable to develop more effective agents 
for the treatment of AD. The increasing mortality rate and the reduced therapeutic potential of the 
currently available options have led us to focus our research activities on the development of potential 
cholinesterase inhibitors for the treatment of AD. 
Among the five-membered heterocyclic systems, spiropyrrolidines occupy an important place as 
this structural motif appears as an integral part of many natural products besides exhibiting 
anticonvulsant [4–6], potential antileukemic [7], local anaesthetic [8] and antiviral activities [9]. Ionic 
liquids are widely recognized as “green” solvents in organic synthesis because of their unique 
properties, such as low vapor pressure, high chemical and thermal stability, solvating ability,  
non-flammability, behavior as acidic or basic catalysts and recyclability [10–14]. In this context, ionic 
liquids have emerged as new green solvents to replace the volatile organic compounds and they are 
found suitable for executing many diverse organic reactions [15–17]. The development of  
multi-component reactions in ionic liquids, although relatively unexplored [18–22] is of great interest 
and to the best of our knowledge, this is the first report on 1,3-dipolar cycloaddition reaction of  
2-arylmethylidene-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one with an unexplored and new class of 
azomethine ylide generated in situ from L-phenylalanine and isatin in ionic liquid medium, namely  
1-butyl-3-methylimidazolium bromide ([bmim]Br).  
As a part of our ongoing research project aimed at identifying potential cholinesterase inhibitors for 
AD therapy [23–33], we report here our efforts in search of novel potent cholinesterase inhibitors 
using dipolar cycloaddition strategy. In addition, molecular modeling studies were also performed to 
disclose the binding modes of the most active inhibitors to the amino acid residues that compose the 
active site of the AChE enzyme. 
2. Results and Discussion 
2.1. Chemistry 
The target spiropyrrolidines 4a–j were synthesized as outlined in Scheme 1. The required starting 
precursors 2-arylmethylidene-5,6-dimethoxy-2,3-dihydro-1H-inden-1-ones 1a–j were synthesized 
following the synthetic protocol reported earlier by us [34] by the reaction of 5,6-dimethoxy-1-
indanone with appropriate aromatic aldehydes in dilute methanolic sodium hydroxide. The three 
component 1,3-dipolar cycloaddition reaction of a series of 1a–j with a new class of relatively 
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unexplored azomethine ylide generated in situ from isatin (2) and phenylalanine (3) in [bmim]Br 
afforded the functionalized spiropyrrolidines 4a–j in good yields. 
 
Scheme 1. Synthesis of spiropyrrolidines 4a–j. 
Solvent optimization for this cycloaddition reaction was investigated by choosing the model 
reaction between azomethine ylide and 2-(2-methylphenyl)methylidene-5,6-dimethoxy-2,3-dihydro-
1H-inden-1-one (1b). The reaction of an equimolar mixture of 1b, isatin and phenylalanine in 
refluxing methanol, methanol:dioxane and dioxane for 5 h afforded the spiropyrrolidine (4b) in 44%, 
52% and 58% yield whilst the reaction in [bmim]Br furnished 4b in an excellent yield of 87% in a 
short reaction time of 1 h, suggesting [bmim]Br as the appropriate solvent in terms of enhanced yield 
and reaction time for the cycloaddition reactions of this kind. Having determined the optimal 
conditions, all the subsequent reactions were effected by heating an equimolar mixture of the reactants 
in [bmim]Br (200 mg) in an oil-bath at 100 °C for 1 h. After completion of the reaction as evidenced 
by TLC, the product was isolated and purified through column chromatography, whilst the ionic liquid 
is recovered and reused, its efficacy being significantly undiminished in subsequent runs. As shown in 
Table 1, the cycloaddition reaction works well regardless of the position and electronic or steric properties 
of the substituents at the aromatic ring of compound 1 affording the cycloadduct 4 in good yields.  
The structure of spiropyrrolidines 4 was elucidated unambiguously with the help of one and  
two-dimensional NMR spectroscopic studies. As a representative case the chemical shift assignments 
of 4b are discussed. In the 1H-NMR spectra of 4b, the doublet at 4.10 ppm (J = 8.8 Hz) can be 
assigned to H-4'. H,H-COSY correlation of H-4' assigns the multiplet at 4.95–5.01 ppm to H-5'. The 
C,H-COSY correlation of H-4' and H-5' assigns the carbon signals at 55.44 and 64.85 ppm to C-4' and 
C-5', respectively. Further, the H,H-COSY correlation of H-5' assigns the doublet of doublets at 2.93  
(J = 14.0, 8.8 Hz) and 3.02 (J = 14.0, 4.4 Hz) to the benzylic protons (6'-CH2). The C,H-COSY 
correlation of 6'-CH2 assigns the carbon signal at 40.45 ppm to C-6'. The remaining doublets at 2.62 
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and 2.73 ppm (J = 18.3 Hz) are due to 3-CH2. Further, H-4' shows HMBCs with the C=O of indanone 
ring, C-5', C-6', C-3 besides showing correlation with the aromatic ring carbons. The carbon signals at 
66.69 and 75.08 ppm are due to the spiro carbons C-3' and C-2', respectively. The carbon chemical shifts of 
C-3, C-4', C-5' and C-6' were also confirmed from DEPT 135 NMR spectrum (vide supplementary 
Materials).The singlets at 1.92, 3.70, 3.80 and 8.01 ppm can be attributed to the methyl, two methoxy 
of aromatic rings and the NH group of oxindole ring, respectively. The aromatic protons appear as 
singlets, doublets and multiplets around 6.19–8.05 ppm. The signals at 179.63 and 207.10 ppm are due 
to the carbonyl groups of oxindole and indanone ring, respectively. The structure of other 
spiropyrrolidines was also assigned by similar straightforward considerations. The stereochemistry of 
compound 4b has been arrived from its NOESY spectra. 
Table 1. Physical data, AChE and BChE inhibitory activities of 4a–j. 
Entry Comp 4 R Yield (%) a mp °C 
AChE Inhibition 
IC50 µM (±SD) 
BChE Inhibition 
IC50 µM (±SD) 
1 a H 85 134–135 11.29 ± 0.21 15.73 ± 0.22 
2 b 2-CH3 87 141–142 10.15 ± 0.17 21.32 ± 0.19 
3 c 2-OCH3 82 126–127 12.23 ± 0.19 11.39 ± 0.12 
4 d 2-Cl 85 136–137 15.17 ± 0.22 9.63 ± 0.15 
5 e 3-OCH3 84 127–128 2.13 ± 0.11 17.44 ± 0.23 
6 f 3-O2N 89 133–134 1.57 ± 0.09 15.32 ± 0.18 
7 g 4-CH3 92 138–139 7.11 ± 0.13 10.46 ± 0.24 
8 h 4-OCH3 80 129–130 3.67 ± 0.15 14.69 ± 0.17 
9 i 4-Cl 88 132–133 5.83 ± 0.20 16.11 ± 0.15 
10 j 2,4-Cl2 90 135–136 6.72 ± 0.18 12.79 ± 0.25 
11 Galantamine - - - 2.09 ± 0.07 19.21 ± 0.12 
12 Donepezil - - - 0.21 ± 0.02 3.6 ± 0.11 
a Isolated yield. 
A mechanism proposed to rationalize the formation of 4 is summarized in Scheme 2. Hydrogen 
atom of [bmim]+ being electron-deficient could form hydrogen bond between the imidazole ring 
hydrogen atom of [bmim]+ and the carbonyl group of isatin facilitating the attack of lone pair of 
phenylalanine on isatin and subsequent dehydration to furnish azomethine ylide 5. In the same way, 
hydrogen atom of [bmim]+ forms hydrogen bond with the carbonyl group of 2-arylmethylidene-5,6-
dimethoxy-2,3-dihydro-1H-inden-1-one providing the easy addition of azomethine ylide to the more 
electron deficient β-carbon to afford spiropyrrolidine 4, regio- and stereoselectively. 
The presence of NH and benzyl groups in adjacent positions of the pyrrolidine ring of 4 prompted 
us to explore their further reaction with paraformaldehyde (Pictet–Spengler cyclisation) in the presence 
of trifluoroacetic acid to synthesize novel isoquinoline heterocyclic hybrids. Thus, the spiropyrrolidine 
(4b) (1 mmol) was treated overnight with paraformaldehyde (1 mmol) in the presence of a catalytic 
amount of trifluoroacetic acid (10 mol %) in CH2Cl2 at room temperature (Scheme 3). This reaction 
afforded the mixture of products with same Rf value, which could not be separated through  
column chromatography. 
  




Scheme 2. Plausible mechanism for the formation of spiropyrrolidine 4. 
 
Scheme 3. Pictet-Spengler cyclisation of spiropyrrolidine 4b. 
2.2. Cholinesterase Inhibitory Activity Study 
All newly synthesized compounds were evaluated in vitro for their cholinesterase inhibitory activity 
against AChE enzyme from electric eel and BChE enzyme from equine serum. As summarized in  
Table 1, compound 4f, bearing nitro moiety at meta position of aromatic ring displayed highest  
AChE inhibitory activity with calculated IC50 value of 1.57 µM, followed by 4e (Ar=m-OCH3),  
4h (Ar=p-OCH3), 4i (Ar=p-Cl), 4j (Ar=o,p-Cl2) and 4g (Ar=p-CH3) all displaying remarkable IC50 
values of lower than 10 µM. The rest of the compounds 4a–d displayed moderate AChE inhibitory 
activities ranging from 10.15–15.17 µM. From Table 1, it is clear that the presence of electron 
withdrawing nitro moiety, had greater impact on the AChE inhibitory potencies compared to electron 
donating moieties such as methoxy (strong electron donor), methyl and chloro (mild electron donor). 
The active site of AChE enzyme is located at bottom of a narrow channel composed of amino acid 
residues with aromatic side chains such as tryptophan and tyrosine. The potency of inhibitors is closely 
related to the ease of insertion into this channel and their ability to interact with its composing 
residues. In fact, inhibitors having more facilitated insertion and better interactions with this gorge 
should possess higher enzyme inhibitory potentials. Thus, the inhibitor 4f, owing to the unique 
electronic withdrawing nature of its nitro group, strongly binds to the AChE active site and effectively 
inhibited choline substrate hydrolysis. Interestingly, compounds bearing a strong electron donor 
methoxy moiety, also showed good inhibitory activities but at much lower degree when compared to 
those containing a nitro group. 
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It is also worth to mention that these newly compounds are benefited from their specific chemical 
structure of including three aromatic cores, by showing moderate to weak BChE inhibitory potencies 
with calculated IC50 values ranging from 9.63–21.32 µM and good selectivity toward AChE enzyme. 
The aromatic core multiplicity effect explains how compounds bearing three aromatic cores have 
higher AChE inhibitory potencies than their analogs with only two aromatic cores and introduces the 
aromatic content of inhibitor as an important factor to design potent AChE inhibitors [28]. 
Compared to standard drugs, galantamine and donepezil, compound 4f displayed significantly 
higher and compound 4e showed comparable AChE inhibitory activity to galantamine. None of the 
inhibitors had comparable activity to donepezil, due to its different planar chemical structure. For 
BChE, except for compound 4b, all the inhibitors showed higher activities than galantamine. As 
expected, none of the compounds showed comparable BChE activity to donepezil. 
2.3. Molecular Docking Studies 
The most active AChE inhibitor, compound 4f was docked into the active site of AChE enzyme 
derived from the crystal structure of Torpedo californica in complex with donepezil (Figure 1). 
Molecular docking analysis clearly demonstrated the influence of aromatic core multiplicity in the 
remarkable activity observed for this compound. Compound 4f strongly bounded to the residues 
having aromatic side chains such as Trp279, Tyr70, Tyr334 and Phe331, which compose peripheral 
anionic site (PAS) of the AChE enzyme through hydrophobic interactions took place dominantly 
between their aromatic entities. It was proposed that deposition of neurotoxin amyloid plaque in AD 
could be accelerated or even triggered by interaction of β-amyloids with the peripheral anionic site of 
the enzyme. Therefore, PAS inhibitors not only symptomatically improve the AD by blocking active 
site gorge entrance and prevention of acetylcholine hydrolysis, but also can have effective disease 
modifying properties [35]. 
 
 
Figure 1. Schematic representation of compound 4f bounded to active site of AChE enzyme. 
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3. Experimental Section 
3.1. General Methods 
Melting points were measured using open capillary tubes and are uncorrected. 1H- and 13C-NMR 
spectra were recorded on Jeol 500 and 400 MHz instruments (Tokyo, Japan) in CDCl3 using TMS as 
internal standard. Chemical shifts are given in parts per million (δ scale) and coupling constants are 
given in Hertz. IR spectra were recorded on a PerkinElmer spectrum 100 FT-IR instrument (KBr 
pellet, Shelton, AL, USA). Elemental analyses were performed 10 on a PerkinElmer 2400 Series II 
Elemental CHNS analyzer (Waltham, MA, USA). Column chromatography was performed on silica gel 
(230–400 mesh) using petroleum spirit/ethyl acetate as eluent. 
3.2. General Procedure for the Synthesis of 4 
An equimolar mixture of 2-arylmethylidene-5,6-dimethoxy-2,3-dihydro-1H-inden-1-one (1), isatin 
(2) and phenylalanine (3) was heated with stirring at 100 °C in 200 mg of [bmim]Br for 1 h. After 
completion of the reaction (TLC), ethyl acetate (10 mL) was added and the reaction mixture stirred for 
15 min. The ethyl acetate layer was separated, washed with water and dried. The product obtained in 
good yield was purified through column chromatography. [bmim]Br after extraction of the product 
was completely dried under vacuum and reused for subsequent reactions. 
3.3. Characterization Data for Compounds 4a–j 
5'-Benzyl-5,6-dimethoxy-2,3-dihydro-4'-phenyldispiro[1H-indene-2,3'-pyrrolidine-2',3''-indoline]-
1,2''-dione (4a). IR (KBr) νmax 3405, 1721, 1685, 1620, 1594 cm−1; 1H-NMR (400 MHz, CDCl3): δH 
2.65 (d, J = 17.6 Hz, 1H, 3-CH2), 2.86–2.97 (m, 2H, 3-CH2 and 6'-CH2), 3.04–3.08 (m, 1H, 6'-CH2), 
3.65 (s, 3H, OCH3), 3.78 (s, 3H, OCH3), 3.94 (d, J = 8.8 Hz, 1H, H-4'), 4.70–4.81 (m, 1H, H-5'), 6.19 
(s, 1H, Ar-H), 6.58 (d, J = 7.2 Hz, 1H, Ar-H), 6.86–7.40 (m, 14H, Ar-H), 8.37 (s, 1H, NH). 13C-NMR 
(100 MHz, CDCl3): δC 34.27 (C-3), 40.10 (C-6'), 56.09 (OCH3), 56.15 (OCH3), 59.47 (C-4'), 64.00  
(C-5'), 67.16 (C-3'), 74.96 (C-2'), 104.08, 106.49, 109.63, 122.52, 126.37, 128.30, 128.45, 129.19, 
129.27, 129.40, 129.62, 129.74, 130.21, 135.48, 136.57, 138.85, 148.17, 149.42, 155.44, 180.13  
(C-2''), 206.35 (C-1). Anal. calcd for C34H30N2O4: C, 76.96; H, 5.70; N, 5.28. Found: C, 76.82; H, 
5.47; N, 5.19%. 
5'-Benzyl-5,6-dimethoxy-2,3-dihydro-4'-(2-methylphenyl)dispiro[1H-indene-2,3'-pyrrolidine-2',3''-
indoline]-1,2''-dione (4b). IR (KBr) νmax 3427, 1720, 1687, 1619, 1591 cm−1; 1H-NMR (400 MHz, 
CDCl3): δH 1.92 (s, 3H, CH3), 2.62 (d, J = 18.32 Hz, 1H, 3-CH2), 2.73 (d, J = 18.32 Hz, 1H, 3-CH2), 
2.93 (dd, J = 13.96, 8.0 Hz, 1H, 6'-CH2), 3.02 (dd, J = 13.92, 4.4 Hz, 1H, 6'-CH2), 3.70 (s, 3H, OCH3), 
3.80 (s, 3H, OCH3), 4.10 (d, J = 8.8 Hz, 1H, H-4'), 4.95–5.01 (m, 1H, H-5'), 6.19 (s, 1H, Ar-H), 6.57 
(d, J = 7.32 Hz, 1H, Ar-H), 6.86 (t, J = 7.32 Hz, 1H, Ar-H), 6.90 (s, 1H, ArH), 6.99–7.31 (m, 9H,  
Ar-H), 7.36 (d, J = 7.36 Hz, 1H, Ar-H), 8.01 (s, 1H, NH), 8.04 (d, J = 8.0 Hz, 1H, Ar-H). 13C-NMR  
(100 MHz, CDCl3): δC 20.33 (CH3), 35.16 (C-3), 40.45 (C-6'), 55.44 (C-4'), 55.95 (OCH3), 56.04 
(OCH3), 64.85 (C-5'), 66.69 (C-3'), 75.08 (C-2'), 103.96, 106.41, 109.35, 122.51, 126.13, 126.23, 
126.51, 126.69, 127.05, 127.71, 128.23, 129.00, 129.14, 129.66, 130.08, 137.46, 137.91, 138.92, 
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140.92, 148.09, 149.27, 155.36, 179.63 (C-2''), 207.10 (C-1). Anal. calcd for C35H32N2O4: C, 77.18; H, 
5.92; N, 5.14. Found: C, 77.39; H, 5.78; N, 5.02%. 
5'-Benzyl-5,6-dimethoxy-2,3-dihydro-4'-(2-methoxyphenyl)dispiro[1H-indene-2,3'-pyrrolidine-2',3''-
indoline]-1,2''-dione (4c). IR (KBr) νmax 3429, 1722, 1688, 1621, 1595 cm−1; 1H-NMR (400 MHz, 
CDCl3): δH 2.40–2.54 (m, 2H, 3-CH2), 2.91–3.09 (m, 2H, 6′-CH2), 3.66 (s, 3H, OCH3), 3.69 (s, 3H, 
OCH3) 3.87 (s, 3H, OCH3), 4.14 (d, J = 9.2 Hz, 1H, H-4'), 5.02–5.10 (m, 1H, H-5'), 6.10 (s, 1H, Ar-H), 
6.53 (d, J = 7.2 Hz, 1H, Ar-H), 6.61 (d, J = 8.0 Hz, 1H, Ar-H), 6.82–7.40 (m, 11H, Ar-H), 7.80 (d,  
J = 7.2 Hz, 1H, Ar-H), 8.59 (s, 1H, NH). 13C-NMR (100 MHz, CDCl3): δC 34.72 (C-3), 41.02 (C-6'), 
53.48 (C-4'), 54.41 (OCH3), 56.13 (OCH3), 61.68 (OCH3), 65.53 (C-5'), 67.15 (C-3'), 75.01 (C-2'), 
104.11, 106.40, 109.52, 109.79, 120.65, 122.59, 126.16, 126.67, 127.71, 128.15, 128.30, 128.98, 
129.15, 129.25, 135.42, 139.34, 148.72, 149.09, 155.06, 158.17, 179.63 (C-2''), 208.06 (C-1). Anal. 
calcd for C35H32N2O5: C, 74.98; H, 5.75; N, 5.00. Found: C, 75.21; H, 5.61; N, 5.12%. 
5'-Benzyl-5,6-dimethoxy-2,3-dihydro-4'-(2-chlorophenyl)dispiro[1H-indene-2,3'-pyrrolidine-2',3''-
indoline]-1,2''-dione (4d). IR (KBr) νmax 3422, 1716, 1684, 1620, 1595 cm−1; 1H-NMR (400 MHz, 
CDCl3): δH 2.51 (d, J = 18.0 Hz, 1H, 3-CH2), 2.64 (d, J = 18.0 Hz, 1H, 3-CH2), 2.96–3.10 (m, 2H,  
6'-CH2), 3.69 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), 4.39 (d, J = 8.8 Hz, 1H, H-4'), 4.92–4.99 (m, 1H,  
H-5′), 6.30 (s, 1H, Ar-H), 6.60 (d, J = 7.6 Hz, 1H, Ar-H), 6.92–7.47 (m, 10H, Ar-H), 7.95 (s, 1H, 
ArH), 8.07 (d, J = 7.6 Hz, 1H, Ar-H), 8.36 (s, 1H, NH). 13C-NMR (100 MHz, CDCl3): δC 34.77 (C-3), 
40.78 (C-6'), 56.28 (OCH3), 56.39 (OCH3), 61.10 (C-4'), 66.28 (C-5'), 67.16 (C-3'), 75.37 (C-2'), 
105.27, 106.54, 107.18, 109.66, 122.72, 126.81, 127.95, 128.26, 128.56, 129.08, 129.18, 129.84, 
131.11, 133.87, 136.13, 137.39, 138.53, 149.39, 149.78, 155.45, 179.60 (C-2''), 207.11 (C-1). Anal. 
calcd for C34H29ClN2O4: C, 72.27; H, 5.17; N, 4.96. Found: C, 72.06; H, 5.41; N, 4.87%. 
5'-Benzyl-5,6-dimethoxy-2,3-dihydro-4'-(3-methoxyphenyl)dispiro[1H-indene-2,3'-pyrrolidine-2',3''-
indoline]-1,2''-dione (4e). IR (KBr) νmax 3438, 1716, 1692, 1618, 1587 cm−1; 1H-NMR (400 MHz, 
CDCl3): δH 2.69 (d, J = 17.6 Hz, 1H, 3-CH2), 2.88–3.10 (m, 3H, 3-CH2 and 6'-CH2), 3.67 (s, 3H, 
OCH3), 3.72 (s, 3H, OCH3) 3.77 (s, 3H, OCH3), 4.08 (d, J = 8.8 Hz, 1H, H-4'), 4.75–4.82 (m, 1H,  
H-5'), 6.22 (s, 1H, Ar-H), 6.60 (d, J = 8.0 Hz, 1H, Ar-H), 6.71–7.28 (m, 13H, Ar-H), 8.72 (s, 1H, NH). 
13C-NMR (100 MHz, CDCl3): δC 34.42 (C-3), 40.28 (C-6'), 55.22 (OCH3), 56.02 (OCH3), 56.14 
(OCH3), 60.00 (C-4'), 64.26 (C-5'), 67.14 (C-3'), 74.94 (C-2'), 104.10, 106.65, 109.71, 112.54, 115.79, 
122.53, 122.74, 123.17, 126.31, 128.10, 128.40, 129.21, 129.36, 129.40, 138.79, 140.45, 148.29, 
149.32, 155.52, 159.68, 180.27 (C-2''), 206.44 (C-1). Anal. calcd for C35H32N2O5: C, 74.98; H, 5.75; 
N, 5.00. Found: C, 75.10; H, 5.86; N, 5.08%. 
5'-Benzyl-5,6-dimethoxy-2,3-dihydro-4'-(3-nitrophenyl)dispiro[1H-indene-2,3'-pyrrolidine-2',3''-
indoline]-1,2''-dione (4f). IR (KBr) νmax 3425, 1721, 1684, 1623, 1590 cm−1; 1H-NMR (400 MHz, 
CDCl3): δH 2.55 (d, J = 17.6 Hz, 1H, 3-CH2), 2.90 (d, J = 17.6 Hz, 1H, 3-CH2), 2.94–2.98 (m, 1H, 6'-CH2), 
3.10–3.19 (m, 1H, 6'-CH2), 3.73 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), 3.88 (d, J = 8.8 Hz, 1H, H-4′),  
4.78–4.84 (m, 1H, H-5'), 6.39 (s, 1H, Ar-H), 6.68 (d, J = 7.2 Hz, 1H, Ar-H), 6.85–7.86 (m, 10H,  
Ar-H), 7.67 (d, J = 7.2 Hz, 1H, Ar-H), 7.97 (d, J = 8.0 Hz, 1H, Ar-H), 8.28 (s, 1H, ArH), 8.47 (s, 1H, 
NH). 13C-NMR (100 MHz, CDCl3): δC 34.52 (C-3), 40.76 (C-6'), 56.12 (OCH3), 56.18 (OCH3), 60.09 
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(C-4'), 65.47 (C-5'), 67.16 (C-3'), 75.15 (C-2'), 104.32, 106.69, 109.70, 122.84, 122.98, 126.41, 
126.53, 126.78, 127.82, 128.36, 129.18, 129.27, 136.75, 137.93, 141.00, 141.72, 147.74, 148.29, 
149.66, 155.90, 179.76 (C-2''), 206.80 (C-1). Anal. calcd for C34H29N3O6: C, 70.94; H, 5.08; N, 7.30. 
Found: C, 70.68; H, 5.25; N, 7.41%. 
5'-Benzyl-5,6-dimethoxy-2,3-dihydro-4'-(4-methylphenyl)dispiro[1H-indene-2,3'-pyrrolidine-2',3''-
indoline]-1,2''-dione (4g). IR (KBr) νmax 3420, 1723, 1691, 1620, 1589 cm−1; 1H-NMR (400 MHz, 
CDCl3): δH 2.30 (s, 3H, CH3), 2.67 (d, J = 17.6 Hz, 1H, 3-CH2), 2.85–2.94 (m, 2H, 3-CH2 and 6'-CH2), 
3.07 (dd, J = 14.0, 2.8 Hz, 1H, 6'-CH2), 3.66 (s, 3H, OCH3), 3.77 (s, 3H, OCH3), 3.81 (d, J = 10.4 Hz, 
1H, H-4'), 4.75–4.82 (m, 1H, H-5'), 6.14 (s, 1H, Ar-H), 6.56 (d, J = 8.0 Hz, 1H, Ar-H), 6.83–7.29 (m, 
13H, Ar-H), 8.48 (s, 1H, NH). 13C-NMR (100 MHz, CDCl3): δC 21.15 (CH3), 34.24 (C-3), 40.13  
(C-6'), 56.01 (OCH3), 56.14 (OCH3), 59.44 (C-4'), 63.92 (C-5'), 67.21 (C-3'), 74.84 (C-2'), 104.07, 
106.61, 109.65, 122.54, 126.31, 128.22, 128.43, 129.14, 129.26, 129.37, 129.60, 129.75, 130.15, 
135.45, 136.62, 138.87, 148.16, 149.30, 155.46, 180.26 (C-2''), 206.25 (C-1). Anal. calcd for 
C35H32N2O4: C, 77.18; H, 5.92; N, 5.14. Found: C, 77.43; H, 5.74; N, 5.01%. 
5'-Benzyl-5,6-dimethoxy-2,3-dihydro-4'-(4-methoxyphenyl)dispiro[1H-indene-2,3'-pyrrolidine-2',3''-
indoline]-1,2''-dione (4h). IR (KBr) νmax 3426, 1722, 1691, 1622, 1596 cm−1; 1H-NMR (400 MHz, 
CDCl3): δH 2.69 (d, J = 17.6 Hz, 1H, 3-CH2), 2.85–2.96 (m, 2H, 3-CH2 and 6'-CH2), 3.03–3.08 (m, 1H, 
6'-CH2), 3.71 (s, 3H, OCH3), 3.76 (s, 3H, OCH3), 3.78 (s, 3H, OCH3), 3.85–3.98 (m, 1H, H-4'),  
3.67–3.75 (m, 1H, H-5'), 6.29 (s, 1H, Ar-H), 6.57 (d, J = 7.2 Hz, 1H, Ar-H), 6.79–7.62 (m, 13H,  
Ar-H), 8.09 (s, 1H, NH). 13C-NMR (100 MHz, CDCl3): δC 34.15 (C-3), 40.22 (C-6'), 55.27 (OCH3), 
56.04 (OCH3), 56.15 (OCH3), 59.16 (C-4'), 64.12 (C-5'), 67.26 (C-3'), 74.73 (C-2'), 104.13, 106.70, 
109.51, 113.88, 122.58, 126.31, 128.30, 128.42, 129.15, 129.35, 130.58, 131.31, 132.42, 138.89, 
148.18, 149.31, 155.49, 158.55, 180.01 (C-2''), 206.30 (C-1). Anal. calcd for C35H32N2O5: C, 74.98; H, 
5.75; N, 5.00. Found: C, 74.70; H, 5.96; N, 5.13%. 
5'-Benzyl-5,6-dimethoxy-2,3-dihydro-4'-(4-chlorophenyl)dispiro[1H-indene-2,3'-pyrrolidine-2',3''-
indoline]-1,2''-dione (4i). IR (KBr) νmax 3389, 1718, 1685, 1615, 1594 cm−1; 1H-NMR (400 MHz, 
CDCl3): δH 2.68 (d, J = 17.6 Hz, 1H, 3-CH2), 2.89–2.99 (m, 2H, 3-CH2 and 6'-CH2), 3.06–3.10 (m, 1H, 
6'-CH2), 3.68 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), 3.95 (d, J = 8.8 Hz, 1H, H-4'), 4.72–4.84 (m, 1H,  
H-5'), 6.21 (s, 1H, Ar-H), 6.57 (d, J = 7.6 Hz, 1H, Ar-H), 6.83–7.45 (m, 13H, Ar-H), 8.40 (s, 1H, NH). 
13C-NMR (100 MHz, CDCl3): δC 34.30 (C-3), 40.17 (C-6'), 56.10 (OCH3), 56.22 (OCH3), 59.45 (C-4'), 
64.04 (C-5'), 67.13 (C-3'), 75.05 (C-2'), 104.12, 106.45, 109.62, 122.47, 126.46, 128.35, 128.43, 
129.24, 129.31, 129.47, 129.61, 129.80, 130.29, 135.52, 136.61, 138.87, 148.20, 149.46, 155.49, 
180.21 (C-2''), 206.63 (C-1). Anal. calcd for C34H29ClN2O4: C, 72.27; H, 5.17; N, 4.96. Found: C, 
72.50; H, 5.02; N, 4.87%. 
5'-Benzyl-5,6-dimethoxy-2,3-dihydro-4'-(2,4-dichlorophenyl)dispiro[1H-indene-2,3'-pyrrolidine-2',3''-
indoline]-1,2''-dione (4j). IR (KBr) νmax 3394, 1721, 1682, 1614, 1583 cm−1; 1H-NMR (400 MHz, 
CDCl3): δH 2.47 (d, J = 18.0 Hz, 1H, 3-CH2), 2.62 (d, J = 18.0 Hz, 1H, 3-CH2), 2.93 (dd, J = 14.0,  
5.8 Hz, 1H, 6'-CH2), 2.99 (dd, J = 14.0, 5.8 Hz, 1H, 6'-CH2), 3.72 (s, 3H, OCH3), 3.81 (s, 3H, OCH3), 
4.31 (d, J = 8.8 Hz, 1H, H-4'), 4.84–4.90 (m, 1H, H-5'), 6.30 (s, 1H, Ar-H), 6.59 (d, J = 7.2, 1H, Ar-H), 
Molecules 2015, 20 2305 
 
 
6.84–7.35 (m, 9H, Ar-H), 7.47 (s, 1H, ArH), 7.60 (d, J = 8.8 Hz, 1H, Ar-H), 8.00 (d, J = 8.8 Hz, 1H, 
Ar-H), 8.40 (s, 1H, NH). 13C-NMR (100 MHz, CDCl3): δC 34.66 (C-3), 40.88 (C-6'), 55.67 (OCH3), 
56.08 (OCH3), 64.73 (C-4'), 66.06 (C-5'), 67.15 (C-3'), 75.37 (C-2'), 104.27, 106.55, 109.70, 122.81, 
126.32, 126.51, 127.17, 127.83, 128.30, 128.73, 129.11, 129.53, 132.19, 132.79, 136.16, 136.60, 
138.27, 141.23, 144.96, 148.02, 149.51, 155.59, 179.31 (C-2''), 206.98 (C-1). Anal. calcd for 
C34H28Cl2N2O4: C, 68.12; H, 4.71; N, 4.67. Found: C, 68.30; H, 4.94; N, 4.56%. 
3.4. General Procedure for the Synthesis of 6 
To a stirred solution of 4b (1 mmol) in 5 mL of dry dichloromethane was added paraformaldehyde 
(1 mmol), followed by catalytic amount of trifluoroacetic acid at 0 °C. The reaction mixture was 
allowed to stir overnight and after completion of the reaction, the mixture was washed with water and 
dried over Na2SO4. The solvent was removed under reduced pressure to afford 6b as mixture of 
products with same Rf value, which could not be separated through column chromatography. 
3.5. Cholinesterase Inhibition Assays 
Cholinesterase inhibitory activity of the synthesized compounds was evaluated using the Ellman’s 
microplate assay. For acetylcholinesterase (AChE) inhibitory assay, 140 μL of 0.1 M sodium 
phosphate buffer (pH 8) was first added to a 96-wells microplate followed by 20 μL of test samples 
and 20 μL of 0.09 units/mL acetylcholinesterase enzyme from Electrophoruselectricus (Sigma; St. Louis, 
MO, USA). After 15 min of incubation at 25 °C, 10 μL of 10 mM 5,5'-Dithiobis-2-nitrobenzoic acid 
(DTNB) was added into each well, followed by 10 μL of acetylthiocholine iodide (14 mM). At 30 min 
after the initiation of enzymatic reaction, absorbance of the colored end product was measured using 
BioTek Power Wave X 340 Microplate Spectrophotometer (BioTek; Winooski, VT, USA) at 412 nm. 
For butyrylcholinesterase (BChE) inhibitory assay, the same procedure described above was followed, 
except for the use of enzyme and substrate, instead of which, butyrylcholine esterase from equine 
serum and S-butyrylthiocholine chloride were used. Galanthamine was used as positive control. Test 
samples and galanthamine were prepared in DMSO at an initial concentration of 1 mg/mL (1000 ppm). 
The concentration of DMSO in final reaction mixture was 1%. At this concentration, DMSO has no 
inhibitory effect on acetylcholinesterase enzyme. 
The initial screening was carried out at 10 µg/mL of test samples in 1% DMSO and each test was 
conducted in triplicates. Absorbance of the test samples was corrected by subtracting the absorbance of 
their respective blank. Percentage enzyme inhibition is calculated using the following formula:  
 
(1) 
Subsequently, the determination of IC50 was carried out using a set of five concentrations. 
3.6. Molecular Modeling 
Using GlideTM, (version 5.7, Schrödinger, LLC, New York, NY, USA, 2011), most active 
compound was docked onto the active site of TcAChE derived from three-dimensional structure of the 
enzyme complex with anti-Alzheimer’s drug, galanthamine (PDB ID: 4EVE). 
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Water molecules and hetero groups were deleted from enzyme beyond the radius of 5 Å of 
reference ligand (galanthamine), resulting protein structure refined and minimized by Protein 
Preparation WizardTM (Version 2014-1, Schrödinger, LLC, New York, NY, USA) using OPLS-2005 
force field. Receptor Grid Generation program were used to prepare TcAChE grid and the ligand was 
optimized by LigPrepTM (Version 2014-1, Schrödinger  LLC, New York, NY, USA) program by using 
OPLS-2005 force field to generate lowest energy state. Docking stimulations were carried out on 
bioactive compound, handed in 5 poses per ligand, in which the best pose with highest score was 
displayed for each ligand. 
4. Conclusions 
In conclusion, the synthesis of a series of novel spiropyrrolidines was accomplished via [bmim]Br 
mediated one-pot three component 1,3-dipolar cycloaddition strategy employing a new class of 
azomethine ylide. Among the spiropyrrolidines 4a–j, compound 4f displayed the highest AChE 
enzyme inhibitory activity, Molecular-docking analysis, disclosed binding interactions of this 
compound to the active site residues of the AChE enzyme. 
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